Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783441 · ClinicalTrials.gov registry record · NA
Use of CGM in Kidney Transplant Recipients
A NA study of Diabetes Mellitus, Type 2 and Kidney Transplant; Complications, sponsored by University of California, Davis.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04783441: Recruiting NA study of Diabetes Mellitus, Type 2 and Kidney Transplant; Complications, sponsored by University of California, Davis.
NCT04783441 is a NA study of Diabetes Mellitus, Type 2 and Kidney Transplant; Complications that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 80 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04783441, a NA study of Diabetes Mellitus, Type 2 and Kidney Transplant; Complications, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Primary Outcome
1\) Time in Range: Number of minutes per day or percentage of time that glucose levels are in low (BG\<70), target (BG 70-180), high (BG \>180) or very high (BG\>250) ranges.
Conditions Studied
Interventions
- DEVICE Dexcom G6
- DEVICE Dexcom G6 blinded sensor
Study Locations (1)
California
- UC Davis Health - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT04783441 shows while recruiting
NCT04783441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Dexcom G6 is the first listed.
NCT04783441 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04783441 about?
NCT04783441 is a clinical study titled "Use of CGM in Kidney Transplant Recipients". The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
What is the current status of trial NCT04783441?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2021-06-29. Estimated completion is 2026-12-31.
What conditions does trial NCT04783441 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Kidney Transplant; Complications, Insulin Dependent Diabetes.
What interventions are being tested in trial NCT04783441?
The interventions under investigation include: Dexcom G6 (DEVICE), Dexcom G6 blinded sensor (DEVICE).
Who is sponsoring clinical trial NCT04783441?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04783441 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04783441's enrollment target sits among peer trials
80 217th of 348 higher than 129 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI